Rare diseases
Investigational molecules
Locations
Avenue De Secheron 15, 1202
iOnctura SA supports clinical research in myelofibrosis, with attention to patients whose disease remains unresponsive to JAK inhibitors. The portfolio reflects interest in myeloid neoplasms, bone marrow fibrosis, and immune-mediated mechanisms that influence blood cancer progression.
Research in this area is centred on therapeutic options for advanced blood disorders and on approaches that address persistent disease activity in the haematology setting.
iOnctura SA runs clinical trials in conditions such as Uveal melanoma, Ocular melanoma, Myelofibrosis, Non-small cell lung cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of Roginolisib for Patients with Advanced Uveal Melanoma
ItalyStudy on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors
ItalyStudy of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
